摘要
目的探讨托拉塞米在终末期肥厚型非梗阻性心肌病心力衰竭治疗中的应用效果。方法将本科室收治的60例终末期肥厚型非梗阻性心肌病心力衰竭患者按随机数字表法分为呋塞米组(30例,呋塞米辅助治疗)和托拉塞米组(30例,托拉塞米辅助治疗)。比较两组的治疗效果。结果治疗1周后,托拉塞米组下肢水肿症状分级优于治疗前及呋塞米组(P<0.05)。治疗1周后,两组6min步行试验距离、左室射血分数均改善,且托拉塞米组优于呋塞米组(P<0.05)。治疗1周后,两组血清B型利钠肽、肌钙蛋白T及超敏C反应蛋白水平均降低,且托拉塞米组低于呋塞米组(P<0.05)。托拉塞米组不良反应总发生率低于呋塞米组(P<0.05)。治疗1周后,两组生活质量评分均降低,且托拉塞米组低于呋塞米组(P<0.05)。结论托拉塞米治疗终末期肥厚型非梗阻性心肌病心力衰竭患者效果显著,其不仅能有效缓解患者下肢水肿症状,改善其心功能及血清学指标,还可提高患者生活质量,用药安全性较高。
Objective To investigate the application effect of torasemide in the treatment of end-stage hypertrophic non-obstructive cardiomyopathy with heart failure.Methods Sixty patients with end-stage hypertrophic non-obstructive cardiomyopathy and heart failure admitted in our department were divided into furosemide group (30 cases, furosemide adjuvant therapy) and torasemide group (30 cases, torasemide adjuvant therapy) according to random number table method.The therapeutic effects of the two groups were compared.Results At one week after treatment, the classification of lower extremity edema symptom in the tolasemide group was better than that before treatment and of the furosemide group (P<0.05).At one week after treatment, the 6-minute walking test distance and left ventricular ejection fraction improved in both groups, and those in the tolasemide group were better than the furosemide group (P<0.05).At one week after treatment, the serum levels of B-type natriuretic peptide, troponin T and hypersensitive C-reactive protein in both groups decreased, and those in the tolasemide group were lower than the furosemide group (P<0.05).The total incidence of adverse reactions in the tolasemide group was lower than that in the furosemide group (P<0.05).At one week after treatment, the quality of life scores of both groups reduced, and that in the tolasemide group was lower than the furosemide group (P<0.05).Conclusion Tolasemide is effective in the treatment of end-stage hypertrophic non-obstructive cardiomyopathy with heart failure.It can not only effectively alleviate the lower extremity edema symptom of patients, improve their cardiac function and serological indicators, but also improve the quality of life of patients, and with higher medication safety.
作者
张文博
王强
ZHANG Wen-bo;WANG Qiang(the Hospital of Danfeng County,Shangluo 726200,China)
出处
《临床医学研究与实践》
2019年第15期17-19,共3页
Clinical Research and Practice
关键词
终末期肥厚型非梗阻性心肌病
心力衰竭
托拉塞米
end-stage hypertrophic non-obstructive cardiomyopathy
heart failure
tolasemide
